Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: vegetarian who wrote (7514)	12/16/1997 6:25:00 PM
From: AgAuUSA	Respond to of 14328

''While we're disappointed we were unable to complete a deal this year, we remain committed to reaching an agreement that will be in the best interests of our shareholders,'' said David P. Holveck, president and chief executive officer. ''Without the benefit of an up-front payment in the fourth quarter for the international marketing rights for Avakine, however, earnings for 1997 will fall short of the consensus estimates.'' biz.yahoo.com

To: vegetarian who wrote (7514)	12/16/1997 6:35:00 PM
From: Keiko	Respond to of 14328

M.C., CNTO earnings disappointment should not have any affect on Trinity's operation in the UK. Centocor will do just fine and this is merely a 'speed bump ' for them. CNTO has taken a large multi- million dollar write-off after closing their UK operation and consolidating their operations in the US. They also had a minor set-back in marketing their new Drug for Crohn's Disease ( Avakine ) The Surrey facility which Trinity now operates profitably is a leased building. Trinity expects these diagnostic tests will contribute $ 1.5 million in revenues this year . They paid $ 5 million for the Diagnostic tests which included Toxoplasmosis.......Rubella.....CMV......Herpes.....Syphilis ( all these tests are FDA approved for sale in the US.......( they are listed in Wampole Labs catalog presently ) The Syphilis test is also approved for use in US Blood Bank processing centers. Also included in the sale were 3 new tests.....Chagas....Parovirus...Epstein Barr virus.... Trinity also acquired a license agreement to develope and market " Rapid tests " based on CNTO tumour markers.. I feel Trinity is now contemplating the consolidation of the UK diagnostic business to a new, larger , modern facility in Dublin , Ireland........ I plan to visit Ireland shortly after that takes place ( hopefully ) next spring. to be continued.........